NANOTHERM
LIVE

Serial Number

86297568

Owner

MAGFORCE NT GMBH

Attorney

Shauna M. Wertheim

Filing Date

Jun 2, 2014

Add to watchlist:

No watchlists yet
View on USPTO

NANOTHERM Trademark

Serial Number: 86297568 • Registration: 5047640

NANOTHERM is a trademark filed by MAGFORCE NT GMBH on June 2, 2014. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

MAGFORCE NT GMBH

GERHARD-SEDLMAYR-STRAßE 25
BERLIN 12487 , DE

Entity Type: 27

MagForce AG

Berlin 12489 , DE

Entity Type: 99

NANOTHERM THERAPEUTICS GMBH

GERHARD-SEDLMAYR-STRAßE 25
BERLIN 12487 , DE

Entity Type: 27

Trademark Details

Filing Date

June 2, 2014

Registration Date

September 27, 2016

Published for Opposition

July 12, 2016

Goods & Services

Chemical products, namely, magnetic nanoparticles composed of iron oxide for use in industry and research; chemical metallic or magnetic particles and nanometer particles for use in industry and research; biopolymers containing metallic nanoparticles for use in industry and research; synthetic and natural oxides in the form of granules and granulates containing iron oxide, in particular magnetite and maghemite; chemical products in the form of magnetic nanoparticles, namely, superparamagnetic nanoparticles and superparamagnetic iron oxide nanoparticles for use in industry and research; chemical preparations in the form of biocompatible polymer nanoparticles, liposomes, coated nanoparticles, and drug-containing nanoparticles, all of the foregoing for use in industry and research, namely, for use in therapy methods, thermotherapy methods, thermoablation methods and/or hyperthermia methods, but not including radiotherapy methods

Medical and scientific research in the field of cancer [ and/or cardiovascular treatment ] and diagnosis; development and design of medical devices containing magnetic particles, namely, magnetic nanoparticles, superparamagnetic nanoparticles, and nanoparticles containing iron oxide, all for treatment and/or diagnosis of cancer [ and/or cardiovascular diseases ] ; providing medical testing and information in the field of cancer [ and cardiovascular ] research; none of the foregoing services comprising radiotherapy in cancer treatment

Diagnostic agents for medical purposes, diagnostic preparations for medical purposes, and pharmaceutical, veterinary and medical preparations for the treatment of malignant or benign tumor diseases, [ cardiovascular diseases, arthritis, arthrosis, arteriosclerosis, stenosis, restenosis and/or skin diseases ] containing magnetic particles, namely, magnetic nanoparticles, superparamagnetic nanoparticles, and nanoparticles comprising iron oxide; pharmaceutical preparations containing metallic or magnetic particles in the nature of nanoparticles for use as anticarcinogenic agents and/or antineoplastic agents, and for treating malignant or benign tumor diseases, [ cardiovascular diseases, arthritis, arthrosis, arteriosclerosis, stenosis, restenosis and/or skin diseases ] ; contrasting agents for diagnostic imaging for medical purposes; none of the foregoing to be used with radiotherapy for cancer treatment

[ Medical devices containing magnetic particles, namely, magnetic nanoparticles, superparamagnetic nanoparticles, and nanoparticles containing iron oxide, magnetic powders, granules, and granulates containing iron oxide for use in thermotherapy methods, thermoablation methods and/or hyperthermia methods, and none of the foregoing devices comprising compression equipment systems or apparatus or equipment for radiotherapy ]

Medical services, namely, cancer [ and cardiovascular ] therapy, cancer [ and cardiovascular ] treatment, and medical diagnosis of cancer [ and cardiovascular ] diseases in the nature of dispensing of medical diagnostics and pharmaceutical and medical preparations containing magnetic particles; conducting medical device-based therapeutic or diagnostic methods, namely, providing physical therapy using magnetic nanoparticles, superparamagnetic nanoparticles, and nanoparticles containing iron oxide; medical services, namely, treatment of malignant or benign tumor diseases, [ cardiovascular diseases, arthritis, arthrosis, arteriosclerosis, stenosis, restenosis and/or skin diseases ] ; medical services, namely, thermotherapeutic services, thermoablation methods and/or hyperthermia methods for cancer [ and cardiovascular ] treatment using magnetic nanoparticles, superparamagnetic nanoparticles, and nanoparticles; providing medical testing for diagnostic or treatment purposes in the field of cancer [ and cardiovascular ] treatment; none of the foregoing services comprising radiotherapy in cancer treatment

Filing History

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 15, 2026 ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 8, 2026 ASGN
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Sep 27, 2025 REM2
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Sep 22, 2023 NA85
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Sep 22, 2023 C15P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Sep 22, 2023 APRE
TEAS SECTION 8 & 15 RECEIVED
Mar 22, 2023 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Sep 27, 2021 REM1
CORRECTION UNDER SECTION 7 - PROCESSED
Jan 30, 2017 COC.
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jan 30, 2017 APRE
TEAS SECTION 7 REQUEST RECEIVED
Oct 14, 2016 ES7R
REGISTERED-PRINCIPAL REGISTER
Sep 27, 2016 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 12, 2016 NPUB
PUBLISHED FOR OPPOSITION
Jul 12, 2016 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 22, 2016 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jun 7, 2016 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
May 31, 2016 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 10, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 9, 2016 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 9, 2016 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 9, 2015 GNRN
NON-FINAL ACTION E-MAILED
Nov 9, 2015 GNRT
NON-FINAL ACTION WRITTEN
Nov 9, 2015 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 16, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 16, 2015 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 16, 2015 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 17, 2015 GNRN
NON-FINAL ACTION E-MAILED
Apr 17, 2015 GNRT
NON-FINAL ACTION WRITTEN
Apr 17, 2015 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 26, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 26, 2015 CRFA
ASSIGNED TO LIE
Mar 24, 2015 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 13, 2015 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 15, 2014 GNRN
NON-FINAL ACTION E-MAILED
Sep 15, 2014 GNRT
NON-FINAL ACTION WRITTEN
Sep 15, 2014 CNRT
ASSIGNED TO EXAMINER
Sep 15, 2014 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 13, 2014 NWOS
NEW APPLICATION ENTERED
Jun 5, 2014 NWAP